Answers are grounded in this paper and cite their sources.
Our results show that HIPEC in AOC may be a promising treatment in BRCA wild-type patients, as it seems to balance their decreased chemosensitivity compared to mutation carriers.
No takes yet. Share an insight, caveat, or question.
Ghirardi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: